Grundy RG et al. (2007) Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8: 696–705
Radiotherapy is an effective treatment for childhood intracranial ependymoma (IE), but its use in patients younger than 5 years of age is associated with damage to the central nervous system and an increased risk of a second malignancy. A study by Grundy et al. has examined the role of chemotherapy in children with IE.
The study enrolled 89 children with IE aged 3 years or younger at diagnosis who had not received prior drug or radiation treatment. Following surgery, the children received alternating cycles of myelosuppressive and nonmyelosuppressive chemotherapy for 1 year. Among the 80 patients without metastatic disease, 50 progressed; 34 received radiotherapy for this progression. The 5-year cumulative incidence rate of freedom from radiotherapy in those patients without metastatic disease was 42%. The 3-year and 5-year event-free survival rates for these patients were 47.6% and 41.8%, respectively. The overall 3-year and 5-year survival rates for nonmetastatic patients were 79.3% and 63.4%, respectively. Complete resection did not result in a better outcome, and overall and event-free survival did not differ according to age at diagnosis, site of disease or histological grade. The median time to progression was 1.6 years. The post-chemotherapy 5-year overall survival rates for the patients who received the highest (n = 23) and lowest (n = 32) relative dose intensity of chemotherapy were 76% and 52%, respectively.
This study shows that radiotherapy can be delayed or avoided in children with IE without compromising survival, when these patients are treated with chemotherapy.
Rights and permissions
About this article
Cite this article
Chemotherapy can replace or delay radiotherapy in pediatric intracranial ependymoma. Nat Rev Clin Oncol 5, 6 (2008). https://doi.org/10.1038/ncponc0988
Issue Date:
DOI: https://doi.org/10.1038/ncponc0988